NASDAQ:MLYS Mineralys Therapeutics (MLYS) Stock Price, News & Analysis $29.23 -1.88 (-6.04%) As of 01:47 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Mineralys Therapeutics Stock (NASDAQ:MLYS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Mineralys Therapeutics alerts:Sign Up Key Stats Today's Range$30.01▼$31.9250-Day Range$22.88▼$31.5452-Week Range$12.59▼$47.65Volume1.35 million shsAverage Volume1.14 million shsMarket Capitalization$2.41 billionP/E RatioN/ADividend YieldN/APrice Target$49.33Consensus RatingModerate Buy Company Overview Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. Read More Mineralys Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScoreMLYS MarketRank™: Mineralys Therapeutics scored higher than 77% of companies evaluated by MarketBeat, and ranked 166th out of 868 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingMineralys Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialMineralys Therapeutics has a consensus price target of $49.33, representing about 66.4% upside from its current price of $29.64.Amount of Analyst CoverageMineralys Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Mineralys Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Mineralys Therapeutics are expected to grow in the coming year, from ($2.30) to ($1.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mineralys Therapeutics is -14.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mineralys Therapeutics is -14.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMineralys Therapeutics has a P/B Ratio of 3.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Mineralys Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.50% of the float of Mineralys Therapeutics has been sold short.Short Interest Ratio / Days to CoverMineralys Therapeutics has a short interest ratio ("days to cover") of 8.19.Change versus previous monthShort interest in Mineralys Therapeutics has recently increased by 5.79%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMineralys Therapeutics does not currently pay a dividend.Dividend GrowthMineralys Therapeutics does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment1.05 News SentimentMineralys Therapeutics has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Mineralys Therapeutics this week, compared to 5 articles on an average week. Company Ownership4.2 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $3,000,586.00 in company stock, which represents 0.1227% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Mineralys Therapeutics insiders have bought 68.92% more of their company's stock than they have sold. Specifically, they have bought $7,354,269.00 in company stock and sold $4,353,683.00 in company stock.Percentage Held by Insiders18.94% of the stock of Mineralys Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.46% of the stock of Mineralys Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Mineralys Therapeutics' insider trading history. Receive MLYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mineralys Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MLYS Stock News HeadlinesMineralys Therapeutics, Inc. (MLYS) Presents at 35th European Meeting on Hypertension and Cardiovascular Protection - SlideshowJune 1 at 7:07 PM | seekingalpha.comMineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on ...May 31 at 2:07 PM | markets.businessinsider.comMusk's "Next Starlink"?Musk just received FCC approval for his next major invention - and one chipmaker 148 times smaller than NVIDIA may be at the center of it. According to tech insider Jeff Brown, this company is set to supply Musk with 5 billion chips over the next two years. Brown spent senior executive years at Qualcomm, Juniper Networks, and NXP Semiconductors before identifying this opportunity. He believes early investors could be positioned similarly to those who got in on Starlink before its public release.June 2 at 1:00 AM | Brownstone Research (Ad)Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 MillionMay 31 at 2:07 PM | finance.yahoo.comMineralys Therapeutics Reports Positive Phase 3 Results for Lorundrostat in Reducing Blood Pressure and Albuminuria in Chronic Kidney Disease PatientsMay 30 at 11:31 AM | quiverquant.comQMineralys' pill cuts blood pressure in kidney disease patientsMay 30 at 11:20 AM | reuters.comMineralys Therapeutics (NASDAQ:MLYS) Insider Sells $11,488.35 in StockMay 20, 2026 | insidertrades.comMineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 2,171 SharesMay 14, 2026 | insidertrades.comSee More Headlines MLYS Stock Analysis - Frequently Asked Questions How have MLYS shares performed this year? Mineralys Therapeutics' stock was trading at $36.29 at the beginning of 2026. Since then, MLYS shares have decreased by 18.3% and is now trading at $29.6420. How were Mineralys Therapeutics' earnings last quarter? Mineralys Therapeutics, Inc. (NASDAQ:MLYS) issued its earnings results on Wednesday, May, 6th. The company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.51) by $0.04. Read the conference call transcript. When did Mineralys Therapeutics IPO? Mineralys Therapeutics (MLYS) raised $180 million in an initial public offering (IPO) on Wednesday, February 8th 2023. The company issued 12,000,000 shares at a price of $14.00-$16.00 per share. Who are Mineralys Therapeutics' major shareholders? Top institutional investors of Mineralys Therapeutics include Orbimed Advisors LLC (2.49%), Jennison Associates LLC (1.54%), Bank of America Corp DE (1.33%) and Pictet Asset Management Holding SA (1.25%). Insiders that own company stock include Brian Taylor Slingsby, Ra Capital Management, LP, Samsara Biocapital Gp, Llc, Jon Congleton, Srinivas Akkaraju, David Malcom Rodman, Adam Scott Levy, Daphne Karydas and Alexander M Gold. View institutional ownership trends. How do I buy shares of Mineralys Therapeutics? Shares of MLYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mineralys Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mineralys Therapeutics investors own include Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings5/06/2026Today6/02/2026Jefferies Global Healthcare Conference 20266/03/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 MLYS's financial health is in the Yellow zone, according to TradeSmith. MLYS has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MLYS CIK1933414 Webwww.mineralystx.com Phone888-378-6240FaxN/AEmployees28Year Founded2019Price Target and Rating Average Price Target for Mineralys Therapeutics$49.33 High Price Target$56.00 Low Price Target$30.00 Potential Upside/Downside+68.1%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($2.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$154.65 million Net MarginsN/A Pretax MarginN/A Return on Equity-27.92% Return on Assets-26.98% Debt Debt-to-Equity RatioN/A Current Ratio44.33 Quick Ratio44.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.17 per share Price / Book3.59Miscellaneous Outstanding Shares82,498,000Free Float66,873,000Market Cap$2.42 billion OptionableOptionable Beta0.49 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:MLYS) was last updated on 6/2/2026 by MarketBeat.com Staff. From Our PartnersSecret behind near perfectly timed stock trades…?After 20 years of professional trading, Ross Givens says this is the single most lucrative market strategy he ...Traders Agency | SponsoredThe Rare Earth Shift Few Saw ComingRare earth elements sit inside modern defense systems, high-performance magnets, and advanced electronics - ye...i2i Marketing Group, LLC | SponsoredBNZI posted 169 percent revenue growth - is a turnaround formingBanzai International (NASDAQ: BNZI) reported full-year 2025 revenue of $12.2 million, up 169% year-over-year, ...Huge Alerts | SponsoredHow to claim a stake in SpaceX before the June 12 IPOSpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredGiving “2022 pre-ChatGPT” vibes (but 10x bigger)When ChatGPT launched in 2022, Nvidia surged 1,800% over three years. Now, Nvidia's CEO suggests July 22nd cou...StocksToTrade | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredIf You Have $50k+ on Coinbase, This Will Ruin Your DayOctober 14th, 2025, CNBC quietly published an interview with BlackRock's CEO, who went on live television and ...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mineralys Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
